What is the Gilead Sciences Inc. stock price forecast?

Gilead Sciences Inc. is currently trading at $127.23. View real-time AI analysis on Alpha Lenz.

What is Gilead Sciences Inc. insider trading activity?

View the latest insider trading data for Gilead Sciences Inc. on Alpha Lenz.

What is Gilead Sciences Inc.'s P/E ratio?

Gilead Sciences Inc.'s P/E ratio is 18.6.

Gilead Sciences Inc.

NASDAQ · GILD

$127.23+2.93(+2.36%)Pre-market

Ask about Gilead Sciences Inc.'s future dividend policy...

Alpha Chat Insight

“Gilead Sciences Inc. trades at a P/E of 18.6 (fair value) with strong ROE of 40.5%. Operating margin of 39.7% indicates strong profitability.”

Ask for details →

Company Overview

Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.

CEOMr. Daniel P. O'Day

Websitehttps://www.gilead.com

SectorHealthcare

IndustryDrug Manufacturers - General

Employees17,600

Company Statistics

FY 2025

Profile

$158.27BMarket Cap

$29.44BRevenue

0.00Shares Out

17,600Employees

Margins

78.83%Gross

50.30%EBITDA

39.74%Operating

33.27%Pre-Tax

28.90%Net

Valuation

18.60P/E

6.97P/B

5.38EV/Sales

11.86EV/EBITDA

16.74P/FCF

Growth (CAGR)

2.57%Rev 3Yr

3.58%Rev 5Yr

2.16%Op Inc 3Yr

3.34%Op Inc 5Yr

23.06%Net Inc 3Yr

148.95%Net Inc 5Yr

Returns

14.42%ROA

40.49%ROE

18.34%ROIC

Financial Health

$7.56BCash & Cash Equivalents

$28.84BNet Debt

160.96%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Gilead Sciences Inc. trades at a P/E of 18.6 (fair value) with strong ROE of 40.5%. Operating margin of 39.7% indicates strong profitability.”

Ask for details →

Frequently Asked Questions

Gilead Sciences Inc. (ticker: GILD) is a company listed on NASDAQ in the Healthcare sector (Drug Manufacturers - General). It has approximately 17,600 employees. Market cap is $158.3B.

The current price is $127.23 with a P/E ratio of 18.6x and P/B of 6.97x.

ROE is 40.49% and operating margin is 39.74%. Annual revenue is $29.4B.